金十数据整理：每日港股市场要闻速递（6月6日 周五） 重要新闻： 2. 新华制药(00719.HK)取得二十碳五烯酸乙酯软胶囊药品注册证书。 3. 景瑞控股(01862.HK)前5个月合约签约销售额约3.87亿元，同比下降50.76%。 4. 弘阳地产(01996.HK)前5个月累计合约销售金额为24.7亿元，同比减少39.77%。 5. 融创中国(01918).HK前5个月实现合同销售金额约160亿元，同比减少35.28%。 8. 恒瑞医药(01276.HK)及子公司就注射用SHR-A1811、阿得贝利单抗注射液、苹果酸法米替尼胶囊获药 物临床试验批准通知书。 6. 正荣地产(06158.HK)前5个月累计合约销售金额约19.63亿元，同比减少30.64%。 1. 国家主席习近平应约同美国总统特朗普通电话。 2. 6月6日，中国人民银行将开展10000亿元买断式逆回购操作，期限为3个月。 个股新闻： 7. 东风集团股份(00489.HK)前5个月累计汽车销量为67.28万辆，同比下降约17.1%。 1. 金隅集团(02009.HK)33.64亿竞得北京海淀区住宅用地。 ...

浙江诚意药业股份有限公司 关于 2024 年度暨 2025 年第一季度 业绩说明会召开情况的公告 证券代码：603811 证券简称：诚意药业 公告编号：2025-029 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江诚意药业股份有限公司（以下简称"公司"或"诚意药业"）于 2025 年 https://roadshow.sseinfo.com/通过视频直播和网络互动方式召开 2024 年度暨 一、业绩说明会召开情况 信息媒体披露了《浙江诚意药业股份有限公司关于召开 2024 年度暨 2025 年第一季 度业绩说明会的公告》（公告编号：2025-027）。 副总经理颜丽娜女士、营销中心总经理罗飞跃先生、董事会秘书柯泽慧女士、财务 总监吕孙战先生、独立董事黄明先生出席了本次业绩说明会。与投资者进行互动交 流和沟通，就投资者关注的问题进行了回复。 二、投资者提出的主要问题及公司回复情况 答：感谢您的关注！2024 年氨糖胶囊销售整体表现稳健，延续了近年来的增 长趋势。 销售规模：全年关节类药物营收达 5 亿元，同比增长 23. ...

Group 1 - CICC expects companies like Mixue Group (02097) and Bruker (00325) to be included in the Hong Kong Stock Connect list following the recent adjustments to the Hang Seng Index [1] - Horizon Robotics, listed in October last year, has met the requirements for inclusion in the Hong Kong Stock Connect after being added to the Hang Seng Index in February [1] - CICC estimates that passive fund inflows for companies like ZTO Express and NetEase will be significant, with expected inflows of $128 million and $218 million respectively [1] Group 2 - The Nasdaq Golden Dragon China Index fell by 0.17%, while major US indices showed slight gains, with the Dow Jones up 0.32% [2] - Notable gains were seen in the pharmaceutical and precious metals sectors, with Novavax rising over 15% [2] - The Hang Seng Index ADR increased by 0.52%, indicating a positive sentiment in the Hong Kong market [2] Group 3 - The World Health Organization's Director-General emphasized the need for global cooperation to address unprecedented public health challenges during the 78th World Health Assembly [3] - The WHO faces a budget shortfall of $1.7 billion over the next two years, which poses a significant challenge to its global health mission [3] Group 4 - Huawei's HarmonyOS-powered personal computers were officially launched, marking a significant breakthrough for domestic operating systems in the PC sector [4] - The HarmonyOS computers support over 1,100 external device connections and have adapted over 1,000 applications [4] Group 5 - Shandong Xinhua Pharmaceutical received approval for the listing of Eicosapentaenoic Acid Ethyl Ester, marking a significant milestone in its product development [5] - The approval was granted by the National Medical Products Administration after the company submitted its application in June 2023 [5] Group 6 - Huaxing Capital announced the successful listing of its portfolio company, Weigao Blood Purification Products, on the Shanghai Stock Exchange [6] - Tian Cai Holdings is negotiating to provide instant delivery systems for major online supermarkets, enhancing its service offerings [6] Group 7 - BYD established its European headquarters in Hungary, reinforcing its commitment to long-term development in Europe [7] - The establishment of the headquarters signifies deep integration with the local automotive industry [7] Group 8 - New China Life Insurance was approved to participate in the third batch of long-term investment reform trials, aiming to enhance capital market development [8] - The company plans to establish the third phase of the Honghu Fund to facilitate long-term investments [8] Group 9 - Jianbei Miao Miao expects a significant increase of at least 50% in its annual net profit attributable to shareholders for the fiscal year ending March 31, 2025 [9] Group 10 - Leap Motor reported a revenue of 10.02 billion yuan for Q1 2025, representing a year-on-year growth of 187.1% [10] - The growth was driven by a 162.1% increase in sales volume and a 4.9% increase in revenue per vehicle [10] Group 11 - Alibaba Health reported a 13.2% increase in revenue to 30.598 billion yuan for the fiscal year ending March 31, 2025, with adjusted net profit rising by 35.6% [11] - The company achieved a profit attributable to shareholders of 1.432 billion yuan, marking a 62.14% increase [11] Group 12 - Alibaba Pictures reported a 33% increase in revenue to 6.702 billion yuan for the fiscal year ending March 31, 2025, with a net profit attributable to shareholders of 364 million yuan [12] Group 13 - Trip.com Group reported a net operating revenue of 13.8 billion yuan for Q1 2025, reflecting a 16% year-on-year increase [13] - The net profit attributable to shareholders remained stable at 4.3 billion yuan compared to the previous year [13] Group 14 - CSPC Pharmaceutical received FDA fast track designation for its CPO301 drug, aimed at treating advanced non-small cell lung cancer [14] - The drug has also been approved for clinical trials in China [14]

Policy Developments - Abbott Molecular Inc. has initiated a recall of its automated real-time fluorescent nucleic acid amplification analysis system due to design defects [1] - Other companies including Ortho Clinical Diagnostics, Leica Biosystems, Beckman Coulter, and Aesculap have also recalled products due to various issues such as potential bias in reportable range, incorrect labeling, cross-contamination, and rising complaint trends [1] Drug and Device Approvals - Jianyou Co., Ltd. has received FDA approval for the production site transfer of its Idarubicin Hydrochloride Injection in multiple dosages [2] - Xinhua Pharmaceutical has been granted approval for the listing of Eicosapentaenoic Acid Ethyl Ester as a chemical raw material drug [3] Capital Market Activities - Guangzhou Pharmaceutical, a subsidiary of Baiyunshan, will be listed on the New Third Board starting May 20, 2025 [4] - Chuangxin International has completed nearly 100 million RMB in Series B financing led by Yueke Fund and Zhongshan Haochuang Fund [5] Industry Events - Kanghui Pharmaceutical has won a first-instance judgment in a lawsuit against Kelewei Biopharmaceuticals regarding equity repurchase, requiring Kelewei to pay 2 million RMB in deposit and 35.994 million RMB in repurchase funds [6] - Weigao Blood Purification Products Co., Ltd. has officially listed on the Shanghai Stock Exchange, raising approximately 1.09 billion RMB through its IPO [7] Public Sentiment Alerts - Sanleaf Bio has changed its accounting firm due to disagreements over audit fees [8] Management Changes - Dize Pharmaceutical's executives plan to reduce their shareholdings due to personal financial needs, with specific amounts detailed for each individual [9][10] - Jia Ying Pharmaceutical's CFO has resigned for personal reasons and will no longer hold any position within the company [11]